Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07445022CT.gov RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma | — | Recruiting | — | — | — |
NCT06008106CT.gov Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma | — | Recruiting | — | — | — |
NCT05263453CT.gov HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation | — | Unknown | — | — | — |
NCT05217303CT.gov HL-085 in NRAS-mutated Advanced Melanoma | — | Completed | — | — | — |
NCT03973151CT.gov Study of HL-085 in NRAS Mutant Advanced Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tunlametinib (this asset) | Fudan University | Approved | BB · 67 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Tunlametinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P2 | B · 58 |
| Colorectal Cancer | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tunlametinib in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tunlametinib-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →